Vertex Pharmaceuticals (NASDAQ:VRTX) Sets New 1-Year Low Following Analyst Downgrade
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) reached a new 52-week low on Thursday after Barclays lowered their price target on the stock from $509.00 to $418.00. Barclays currently has an equal weight rating on the stock. Vertex Pharmaceuticals traded as low as $377.85 and last traded at $396.87, with a volume of 2044282 […]
21 Dec 13:32 · The Markets Daily